PAPA JOSEPH C — SEC insider filings
SEC reporting owner CIK 1242215. 35 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 35 filings on record, filed 2020-09-16 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 3 filings — 113,032 shares, $707,859 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 66.
- Largest priced transaction: purchase of 60,000 shares @ $5.83 ($349,800) in Emergent BioSolutions Inc., filed 2025-05-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | President and CEO, Director | 6 | 1 leg · 60,000 sh · $349,800 | — | 8 |
| Prometheus Biosciences, Inc. (RXDX) | Director | 6 | 1 leg · 15,000 sh · $285,000 | — | 12 |
| Candel Therapeutics, Inc. (CADL) | Director | 10 | 2 legs · 38,032 sh · $73,059 | — | 9 |
| Bausch Health Companies Inc. (BHC) | Director | 8 | — | — | 29 |
| Milestone Pharmaceuticals Inc. (MIST) | Director | 4 | — | — | 6 |
| Bausch & Lomb Corp (BLCO) | CEO & Chairman, Director | 1 | — | — | 2 |
Insider filings — PAPA JOSEPH C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 1,325 (derivative) @ $8.68 | EDGAR |
| 2026-07-01 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 1,331 (derivative) @ $8.64 | EDGAR |
| 2026-06-24 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 187,708 @ $0 | EDGAR |
| 2026-04-02 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 2,795 (derivative) @ $4.11 | EDGAR |
| 2026-03-05 | 4 | Emergent BioSolutions Inc. (EBS) | Tax withholding (F): 37,055 @ $8.44 · Grant/award (A): 252,194 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 100,000 · Grant/award (A): 100,000 (derivative) · Grant/award (A): 100,000 (derivative) | EDGAR |
| 2025-06-26 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 64,239 @ $4.67 | EDGAR |
| 2025-06-18 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Emergent BioSolutions Inc. (EBS) | Purchase (P): 60,000 @ $5.83 | EDGAR |
| 2025-03-12 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 282,500 @ $0 · Grant/award (A): 282,500 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Milestone Pharmaceuticals Inc. (MIST) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2024-03-15 | 4 | Emergent BioSolutions Inc. (EBS) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2023-06-29 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 14,240 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Disposition to issuer (D): 7,278 · Disposition to issuer (D): 10,000 · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 27,340 (derivative) · Disposition to issuer (D): 22,652 (derivative) · Disposition to issuer (D): 2,165 (derivative) · +1 more | EDGAR |
| 2023-06-02 | 4 | Prometheus Biosciences, Inc. (RXDX) | Other (J): 10,000 @ $0 · Other (J): 10,000 @ $0 | EDGAR |
| 2023-05-19 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 2,278 @ $0 | EDGAR |
| 2022-12-12 | 4 | Candel Therapeutics, Inc. (CADL) | Purchase (P): 3,014 @ $1.70 · Purchase (P): 35,018 @ $1.94 | EDGAR |
| 2022-08-10 | 4 | Candel Therapeutics, Inc. (CADL) | Grant/award (A): 28,480 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 22,551 (derivative) @ $0 | EDGAR |
| 2022-05-12 | 4 | Bausch Health Companies Inc. (BHC) | Option exercise (M): 116,697 · Option exercise (M): 183,522 · Option exercise (M): 65,911 · Tax withholding (F): 33,714 @ $9.40 · Grant/award (A): 116,697 (derivative) · Option exercise (M): 116,697 (derivative) @ $9.40 · +4 more | EDGAR |
| 2022-05-09 | 4 | Bausch & Lomb Corp (BLCO) | Grant/award (A): 472,222 @ $0 · Grant/award (A): 1,868,131 (derivative) @ $0 | EDGAR |
| 2022-03-07 | 4 | Bausch Health Companies Inc. (BHC) | Tax withholding (F): 12,643 @ $23.61 | EDGAR |
| 2022-03-02 | 4 | Bausch Health Companies Inc. (BHC) | Option exercise (M): 208,231 · Tax withholding (F): 100,351 @ $24.35 · Tax withholding (F): 13,183 @ $24.35 · Tax withholding (F): 13,206 @ $24.35 · Tax withholding (F): 5,115 @ $24.06 · Grant/award (A): 208,231 (derivative) · +1 more | EDGAR |
| 2021-11-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Grant/award (A): 2,165 (derivative) @ $0 | EDGAR |
| 2021-09-15 | 4 | Bausch Health Companies Inc. (BHC) | Tax withholding (F): 3,549 @ $29.19 · Tax withholding (F): 5,010 @ $28.66 | EDGAR |
| 2021-03-16 | 4 | Prometheus Biosciences, Inc. (RXDX) | Purchase (P): 15,000 @ $19 | EDGAR |
| 2021-03-10 | 4 | Bausch Health Companies Inc. (BHC) | Option exercise (M): 317,089 · Grant/award (A): 108,254 @ $0 · Tax withholding (F): 231,188 @ $32.97 · Option exercise (M): 317,089 (derivative) | EDGAR |
| 2021-03-05 | 4 | Bausch Health Companies Inc. (BHC) | Grant/award (A): 74,150 @ $0 · Grant/award (A): 196,464 (derivative) @ $0 | EDGAR |
| 2021-03-03 | 4 | Bausch Health Companies Inc. (BHC) | Tax withholding (F): 28,192 @ $31.42 | EDGAR |
| 2020-09-16 | 4 | Bausch Health Companies Inc. (BHC) | Tax withholding (F): 3,623 @ $15.40 · Tax withholding (F): 5,115 @ $15.91 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1242215 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs